Literature DB >> 6827446

Live and killed vaccines against toxoplasmosis in mice.

H Waldeland, J K Frenkel.   

Abstract

Mice were immunized with live organisms of the different stages (i.e., tachyzoites, bradyzoites, or sporozoites) of Toxoplasma gondii, or with killed tachyzoites with or without adjuvants. The adjuvants used were liposomes, anhydrides of myristic or lauric acid, levamisole and Freund's complete or incomplete adjuvant. The following strains of T. gondii were used: RH, M-7741, the nonpersisting, temperature-sensitive mutants ts-1, ts-4, or ts-5, and the "back mutant" of ts-1 (Pfefferkorn and Pfefferkorn, 1976). The protection afforded was measured by challenge with the pathogenic M-7741 strain. Killed tachyzoites alone, or with adjuvants, offered only slight protection against challenge with M-7741 and no protection against challenge doses that were lethal to all control mice. Chronic infection and live nonpersisting vaccines conveyed a strong immunity to challenge, except strain ts-1. Because it was less pathogenic and did not require chemoprophylaxis, strain ts-4 best fulfilled the requirements for a good vaccine; its effect in hosts other than the mouse remains to be determined. The immunity induced by tachyzoites, bradyzoites, or sporozoites appeared equally strong when challenged with sporozoites.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6827446

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  20 in total

1.  Protective immunity against Toxoplasma gondii in mice induced by a chimeric protein rSAG1/2.

Authors:  Chung-Dar Yang; Gan-Nan Chang; David Chao
Journal:  Parasitol Res       Date:  2003-11-06       Impact factor: 2.289

2.  Immunological comparison of 124 isolates of Toxoplasma gondii.

Authors:  D D Smith; J K Frenkel
Journal:  Parasitol Res       Date:  2003-09-16       Impact factor: 2.289

3.  The use of CpG as an adjuvant to Toxoplasma gondii vaccination.

Authors:  Jennifer A Spencer; Bruce F Smith; Anthony J Guarino; Byron L Blagburn; Henry J Baker
Journal:  Parasitol Res       Date:  2004-01-15       Impact factor: 2.289

Review 4.  Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications.

Authors:  João Paulo Assolini; Virginia Márcia Concato; Manoela Daiele Gonçalves; Amanda Cristina Machado Carloto; Ivete Conchon-Costa; Wander Rogério Pavanelli; Francine Nesello Melanda; Idessania Nazareth Costa
Journal:  Parasitol Res       Date:  2017-05-05       Impact factor: 2.289

5.  Use of chicken embryonated eggs for evaluating the virulence of Toxoplasma gondii.

Authors:  A Setasimy; M Namavari
Journal:  J Parasit Dis       Date:  2015-02-14

6.  Mycobacterial di-O-acyl-trehalose inhibits mitogen- and antigen-induced proliferation of murine T cells in vitro.

Authors:  R Saavedra; E Segura; R Leyva; L A Esparza; L M López-Marín
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

7.  Expression of herpes simplex virus thymidine kinase in Toxoplasma gondii attenuates tachyzoite virulence in mice.

Authors:  J R Radke; M W White
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

8.  Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene.

Authors:  H V Nielsen; S L Lauemøller; L Christiansen; S Buus; A Fomsgaard; E Petersen
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

9.  Protective immunity against Toxoplasma gondii in mice induced by the SAG2 internal image of anti-idiotype antibody.

Authors:  Chung-Dar Yang; Gan-Nan Chang; David Chao
Journal:  Parasitol Res       Date:  2003-10-17       Impact factor: 2.289

10.  Cytotoxic T-lymphocyte-mediated lysis of Toxoplasma gondii-infected target cells does not lead to death of intracellular parasites.

Authors:  K Yamashita; K Yui; M Ueda; A Yano
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.